Galcanezumab
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Migraine
Conditions
Migraine
Trial Timeline
Feb 26, 2024 → Apr 1, 2026
NCT ID
NCT06085144About Galcanezumab
Galcanezumab is a pre-clinical stage product being developed by Eli Lilly for Migraine. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06085144. Target conditions include Migraine.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06085144 | Pre-clinical | Recruiting |
| NCT04158752 | Approved | Completed |
| NCT02959190 | Phase 3 | Completed |
| NCT02797951 | Phase 3 | Completed |
| NCT02836613 | Phase 1 | Completed |
| NCT02614287 | Phase 3 | Completed |
Competing Products
20 competing products in Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABP-450 | AEON Biopharma | Phase 2 | 44 |
| Lasmiditan + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + LY2300559 | Eli Lilly | Phase 2 | 52 |
| lasmiditan 200 mg + Sumatriptan + matching placebo | Eli Lilly | Phase 1 | 33 |
| ABP-450 + Placebo | AEON Biopharma | Phase 2 | 44 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | 52 |
| Ketorolac + Prochlorperazine + Diphenhydramine | Assertio Holdings | Phase 2 | 44 |
| Galcanezumab + Erenumab | Eli Lilly | Approved | 85 |
| Aricept (donepezil hydrochloride) | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| Galcanezumab + Rimegepant + Placebo + Placebo | Eli Lilly | Approved | 85 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | 52 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Lasmiditan | Eli Lilly | Phase 3 | 77 |
| Galcanezumab Prefilled Syringe + Placebo | Eli Lilly | Phase 2 | 52 |
| Emgality 120 MG in 1 ML Prefilled Syringe | Eli Lilly | Approved | 85 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2590443 + Placebo injection + Sumatriptan + Placebo capsule | Eli Lilly | Phase 2 | 52 |